Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
PRNewswire - February 1, 2006
The three microbicides covered under the agreement are in various stages of development and work under different mechanisms of action. They include: Savvy, which is currently in Phase III clinical trials in the U.S. and Africa; UC781 which is in expanded Phase II trials in the U.S. and Thailand and Cyanovirin-N which is in preclinical testing.
Henry Gabelnick, Ph.D., executive director of CONRAD says, "This agreement is great news for everyone interested in developing an effective microbicide. The more partnerships we have like this one, the better our potential is for getting an effective product ready for distribution."
"I am delighted for our two organizations to enter into this agreement. We have collaborated for many years on all aspects of our microbicide development programs, and we have a deep respect for each other's knowledge and expertise. With CONRAD, we feel we have a capable and experienced partner to work with us toward approval of these critically important products," said Anne-Marie Corner, Senior Vice President of Cellegy Pharmaceuticals.
Currently, the highest rates of infection in women are in sub-Saharan Africa and rates are increasing in women in South and Southeast Asia.
CONRAD has been involved in the research of nearly every microbicide currently in clinical trials. They are currently managing a second Phase III trial of a microbicide called Ushercell in Uganda and South Africa, Benin, Burkina Faso and two centers in India. The trials will evaluate Ushercell for the prevention of HIV infection among 2,574 adult women at high risk of acquiring HIV. This study will also assess incidence of genital gonorrhea and chlamydia.
CONRAD is a cooperating agency of USAID committed to improving reproductive health by expanding the contraceptive choices of women and men and by helping to prevent the transmission of HIV/AIDS and other sexually transmitted diseases. CONRAD is administered through the Department of Obstetrics and Gynecology at Eastern Virginia Medical School (EVMS) in Norfolk, VA, with the main office located in Arlington, VA. http://www.conrad.org
Cellegy Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes prescription drugs for the treatment of women's health care conditions, including sexual dysfunction, HIV prevention; and, gastrointestinal disorders. Biosyn, Inc is a wholly owned subsidiary of Cellegy Pharmaceuticals.
Cellegesic(TM) (nitroglycerin ointment), branded Rectogesic(R) outside the United States, is approved and is being marketed in the United Kingdom by ProStrakan, for the treatment of pain associated with chronic anal fissures. A similar formulation of Rectogesic is currently being sold in Australia, New Zealand, Singapore and South Korea.
Fortigel(TM) (testosterone gel), branded Tostrex(R) outside the United States, is marketed in Sweden for the treatment of male hypogonadism also by ProStrakan. Approvals of Rectogesic and Tostrex by the other member states of the European Union are being sought through the Mutual Recognition Procedure.
SOURCE CONRAD
Web Site: http://www.conrad.org
060201
PR060203
Copyright © 2006 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .